Cover Image
市場調查報告書

完全置換型人工心臟的全球市場:醫療設備的開發平台評估

Total Artificial Heart - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 358225
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
完全置換型人工心臟的全球市場:醫療設備的開發平台評估 Total Artificial Heart - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年05月23日 內容資訊: 英文 46 Pages
簡介

本報告提供全球全人工心臟市場上主要的開發中產品 (醫療設備) 及其臨床實驗的進展調查,再加上產品功能·特性比較分析 (臨床實驗的各進展階段) ,還有主要企業簡介及代表性產品,彙整近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 完全置換型人工心臟概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 完全置換型人工心臟的企業:各臨床實驗階段的開發中產品
  • 完全置換型人工心臟:各臨床實驗階段的開發中產品

第5章 完全置換型人工心臟市場:企業·產品概要

  • Abiomed, Inc.
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart, Inc.
  • Foster-Miller, Inc. (Inactive)
  • MicroMed Cardiovascular, Inc.
  • SynCardia Systems, Inc.
  • 東京大學

第6章 完全置換型人工心臟市場:目前的趨勢

第7章 附錄

圖表一覽

目錄
Product Code: GDME0188EPD

GlobalData's Medical Devices sector report, "Total Artificial Heart - Medical Devices Pipeline Assessment, 2016" provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type

Scope

  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Total Artificial Heart Overview

3. Products under Development

  • 3.1. Total Artificial Heart - Pipeline Products by Stage of Development
  • 3.2. Total Artificial Heart - Pipeline Products by Territory
  • 3.3. Total Artificial Heart - Pipeline Products by Regulatory Path
  • 3.4. Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • 3.5. Total Artificial Heart - Ongoing Clinical Trials

4. Total Artificial Heart - Pipeline Products under Development by Companies

  • 4.1. Total Artificial Heart Companies - Pipeline Products by Stage of Development
  • 4.2. Total Artificial Heart - Pipeline Products by Stage of Development

5. Total Artificial Heart Companies and Product Overview

  • 5.1. Abiomed, Inc. Company Overview
    • 5.1.1. Abiomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. BiVacor Pty Ltd Company Overview
    • 5.2.1. BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Carmat SAS Company Overview
    • 5.3.1. Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Cleveland Heart, Inc. Company Overview
    • 5.4.1. Cleveland Heart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Foster-Miller, Inc. (Inactive) Company Overview
    • 5.5.1. Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. MicroMed Cardiovascular, Inc. Company Overview
    • 5.6.1. MicroMed Cardiovascular, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. SynCardia Systems, Inc. Company Overview
    • 5.7.1. SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. The University of Tokyo Company Overview
    • 5.8.1. The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview

6. Total Artificial Heart- Recent Developments

  • 6.1. Apr 13, 2016: World's Leading Artificial Heart Center, La Pitie Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart
  • 6.2. Feb 29, 2016: Early Findings of the 50cc SynCardia Heart Indicate That It Fits Underserved Patients - Women & Adolescents
  • 6.3. Feb 26, 2016: Carmat Raises USD55 Million in Private Placement of Shares
  • 6.4. Jan 26, 2016: Altaris Capital Partners Acquires Minority Interest in Minnetronix for USD20 Million
  • 6.5. Jan 21, 2016: Information regarding the Feasibility study of the CARMAT bioprosthetic artificial heart
  • 6.6. Nov 12, 2015: Arrhythmia Research Technology Reports 2015 Third Quarter Results
  • 6.7. Sep 16, 2015: SynCardia Systems Withdraws IPO for up to USD30 Million
  • 6.8. Aug 31, 2015: Interim Results of the Feasibility Study Presented at the ESC Congress in London
  • 6.9. Aug 18, 2015: The Start of SynCardia Total Artificial Heart Destination Clinical Study Wins Edison Awards' Top Honor
  • 6.10. Jun 15, 2015: SynCardia Systems - TAH-t Companion 2 Driver System - Letter to Health Care Providers
  • 6.11. Jun 03, 2015: Carmat To Implant Artificial Heart In Fourth Patient In Next Three Months

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Total Artificial Heart - Pipeline Products by Stage of Development
  • Table 2: Total Artificial Heart - Pipeline Products by Territory
  • Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path
  • Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Table 5: Total Artificial Heart - Ongoing Clinical Trials
  • Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development
  • Table 7: Total Artificial Heart - Pipeline Products by Stage of Development
  • Table 8: Abiomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: AbioCor II - Product Status
  • Table 10: AbioCor II - Product Description
  • Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: BiVACOR Device - Product Status
  • Table 13: BiVACOR Device - Product Description
  • Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Artificial Heart - Product Status
  • Table 16: Artificial Heart - Product Description
  • Table 17: Carmat SAS - Ongoing Clinical Trials Overview
  • Table 18: Artificial Heart - First-in-man CARMAT's Bioprosthetic Heart Trial For End-stage Heart Failure
  • Table 19: Cleveland Heart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 20: SmartHeart TAH - Product Status
  • Table 21: SmartHeart TAH - Product Description
  • Table 22: Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 23: MagScrew Total Artificial Heart - Product Status
  • Table 24: MagScrew Total Artificial Heart - Product Description
  • Table 25: MicroMed Cardiovascular, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: Pulse Less Total Artificial Heart - Product Status
  • Table 27: Pulse Less Total Artificial Heart - Product Description
  • Table 28: SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: 50cc Total Artificial Heart - Adults Bridge To Transplant - Product Status
  • Table 30: 50cc Total Artificial Heart - Adults Bridge To Transplant - Product Description
  • Table 31: 50cc Total Artificial Heart - Destination Therapy - Product Status
  • Table 32: 50cc Total Artificial Heart - Destination Therapy - Product Description
  • Table 33: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - Product Status
  • Table 34: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - Product Description
  • Table 35: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - Product Status
  • Table 36: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - Product Description
  • Table 37: SynCardia Systems, Inc. - Ongoing Clinical Trials Overview
  • Table 38: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
  • Table 39: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
  • Table 40: 50cc Total Artificial Heart - Adults Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
  • Table 41: The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Total Artificial Heart - Product Status
  • Table 43: Total Artificial Heart - Product Description
  • Table 44: Glossary

List of Figures

  • Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
  • Figure 2: Total Artificial Heart - Pipeline Products by Territory
  • Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
  • Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
  • Figure 5: Total Artificial Heart - Ongoing Clinical Trials
Back to Top